Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 34Carcinoma, Hepatocellular 33Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Lung Neoplasms 9Rectal Neoplasms 8Nasopharyngeal Carcinoma 8Esophageal Neoplasms 6Cholangiocarcinoma 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Carcinoma 3Breast Neoplasms 3Spinocerebellar Degenerations 2Sarcoma 2Recurrence 2Nonsquamous Non-Small Cell Lung Cancer 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Locally Advanced Rectal Cancer 2

Interventions

Ipilimumab 5Radiotherapy 4Nivolumab 4Doxorubicin 4CTLA-4 Antigen 4pembrolizumab 3Gemcitabine 3cabozantinib 2brostallicin 2Sunitinib 2Specimen Handling 2Radiation Dose Hypofractionation 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Docetaxel 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1talimogene laherparepvec 1spartalizumab 1soblidotin 1sintilimab 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Histiocytoma, Malignant Fibrous × sintilimab × Clear all
NCT05017103 2024-12-11

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 9 charts

Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡